Glioblastoma, Cancer
NVCRNovoCure LimitedCatalyst overview
Research summary
This catalyst tracks a Phase 3 update for Optune Gio® w/ radiation therapy & temozolomide (TMZ) in Glioblastoma, Cancer. The expected timing is based on the latest available company guidance and may change.
TRIDENT trial. 1/9/24 Last patient enrolled. Real-World Data at ESMO 2024. 7/24/25- Topline data in H1 2026. 10/30/25:- TRIDENT Phase 3 topline data now guided for Q2 2026 and Optune Gio reimbursement added via the Spanish National Health System. 02/26/26:- TRIDENT Ph3 GBM topline data expected Q2 2026; Czechia and BC now reimburse Optune Gio for newly diagnosed GBM. 04/30/26:- TRIDENT Ph3 newly diagnosed GBM topline data reiterated for Q2 2026. 06/18/26:- TRIDENT topline OS missed; ASTRO 2026 presentation accepted.
Verification
Confirm timing and program details against the company announcement or filing.